Significant improvement of refractory cutaneous lesions of lupus erythematosus with the use of anifrolumab: a report of two cases
Anifrolumab, a monoclonal antibody targeting the interferon-1 receptor, is currently approved for the treatment of moderate- to-severe systemic lupus erythematosus, but emerging evidence highlights its potential efficacy in cases with predominant cutaneous involvement. We present two cases illustrat...
Furkejuvvon:
| Váldodahkkit: | , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Sociedade Portuguesa de Dermatologia e Venereologia
2025-07-01
|
| Ráidu: | Revista da Sociedade Portuguesa de Dermatologia e Venereologia |
| Fáttát: | |
| Liŋkkat: | https://www.portuguesejournalofdermatology.com/frame_eng.php?id=265 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|